Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (11): 1288-1294.doi: 10.12092/j.issn.1009-2501.2020.11.010

Previous Articles     Next Articles

Mechanism and advance of COVID-19 on immune related pathogenesis and immunotherapy

LI Hongpeng 1,2, ZHANG Liu 1,2, LI Qingyun 1,2   

  1. 1 Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 2 Institute of Respiratory Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Received:2020-06-08 Revised:2020-10-22 Online:2020-11-26 Published:2020-12-17

PDF (PC)

272

Abstract: The novel coronavirus pneumonia (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is pandemic globally. The progress and evolution of the disease is closely related to the immune defense function. The host immune promotes virus clearance. The dysfunction of immune compromises virus clearance, and incurs uncontrolled inflammatory response which causes immune pathological injury and makes the disease worse. Therefore, the application of immunotherapy for immune disorders caused by SARS-CoV-2 infection is expected to be an effective strategy for the treatment of COVID-19.

Key words: COVID-19, SARS-CoV-2, immune, drug, therapy

CLC Number: